Full Text
Evaluation of The Cost Saving Potential of Introducing An Etanercept Biosimilar (Benepali®) For The Treatment of All Licensed Adult Etanercept Indications In The UK

Abstract

Authors

E Psachoulia S Keady

Back to Volume 19, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×